rue Paul Vatine
12th Floor ZI des Quatre Chevaliers
Périgny 17180
France
33 5 46 28 62 58
https://www.valbiotis.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees:
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Sebastien Peltier HDR, Ph.D. | Co-Founder, Member of the Management Board & CEO | 318k | N/A | 1978 |
Mr. Sebastien Bessy | COO & Member of the Management Board | 213k | N/A | N/A |
Mr. Pascal Sirvent Ph.D. | CSO & Member of the Management Board | 241k | N/A | N/A |
Ms. Murielle Cazaubiel | CMO & Member of the Management Board | 205k | N/A | N/A |
Mr. Stanislas Sordet | CFO & Member of Management Board | N/A | N/A | N/A |
Ms. Charlotte Jezequel | CPO & Member of Management Board | N/A | N/A | N/A |
Dr. Josep Infesta | Head of Global Business Development | N/A | N/A | N/A |
Valbiotis SA engages in the research and development of health nutrition products to prevent and control metabolic and cardiovascular diseases in France. The company develops TOTUM-63 for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II/III clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with MASLD. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
Valbiotis SA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.